Milestones

1. de Lope Quiñones S, Luque-Ramírez M, Michael Fernández AC, Quintero Tobar A, Quiñones-Silva J, Martínez García MÁ, Insenser Nieto M, Dorado Avendaño B, Escobar-Morreale HF, Nattero-Chávez L. Unveiling Silent Atherosclerosis in Type 1 Diabetes: The Role of Glycoprotein and Lipoprotein Lipidomics, and Cardiac Autonomic Neuropathy. Metabolites 2025 doi: 10.3390/ metabo15010055. A study on the advanced profile of glycoproteins and lipoproteins that demonstrates that it does not improve the diagnostic accuracy of clinical variables in patients with type 1 diabetes mellitus.
2. Luque-Ramírez M, Martínez-García MÁ, Insenser M, Quintero-Tobar A, de Lope Quiñones S, Nattero-Chávez L, Escobar-Morreale HF. Lipoprotein subclasses compensate the classic atherogenic lipid profi le of women with polycystic ovary syndrome, but common antiandrogenic treatments worsen their lipidome. Eur J Endocrinol. 2025 doi: 10.1093/ejendo/lvaf213. This study describes how SOP is associated with a classic atherogenic lipid profile-albeit with a less unfavorable distribution of lipoprotein subclasses-and how antiandrogenic treatments induce adverse lipid changes.
3. Bayona Cebada A, Nattero-Chávez L, De la Calle De la Villa E, Quintero Tobar A, de Lope Quiñones S, Dorado Avendaño B, Fiers T, Kaufman JM, Luque-Ramírez M, Escobar-Morreale HF. Androgen excess disorders remain undiagnosed in one of every four premenopausal women with Type 1 diabetes. Hum Reprod Open. 2025 doi: 10.1093/hropen/hoaf048. A clinical study concluding that 1 in 4 women with type 1 diabetes mellitus (T1D) has hyperandrogenism, primarily PCOS, highlighting the need for systematic screening.
4. Grant awarded for the project "Pathogenesis of functional hyperandrogenism in women with type 1 diabetes mellitus: from genetic and molecular mechanisms to clinical phenotype" under the AES 2025 call for proposals (PI25/00434). Principal Investigators: Dr. Luque and Dr. Escobar-Morreale. This project will enable the clinical and molecular characterization of women with type 1 diabetes mellitus (DM1) and functional hyperandrogenism to improve their fertility, health, and quality of life. 
5. European patent application: "Diagnosis and/or prognosis of polycystic ovary syndrome" (EP25382105.2), based on results generated by the group, proposes new molecular biomarkers to improve the diagnosis and prognosis of PCOS and has potential applications in the development of diagnostic tools for personalized medicine.